Compass

Founded in 2024 and based in Beijing, China, Biocompass (Beijing) Technology Co. , Ltd. , trading as Compass, is an AI application software developer specializing in AI application software development, AI basic software development, computer system services, AI theory and algorithm software development. In July 2026, Compass raised a strategic funding.

Based on its "AI Virtual Cell Platform," Compass is dedicated to simulating real-life processes to enable engineering of cell design, drug development, and treatment plans. It builds multi-species knowledge-enhanced large models, integrating multimodal data such as genomics and transcriptomes to achieve cellular-level dynamic modeling and prediction. The platform has been applied to a variety of cutting-edge fields, including engineered cell CRO services, stem cell drug development, exosome drug pipelines, and γδT cell immunotherapy, forming a closed-loop system integrating "virtual experiments + cell manufacturing + AI drug pipelines. " The company generates revenue by doing research, development and providing AI cell platform and other related services.

The company will use the latest funding to rapidly advance the collection of self-produced data and the development of new models, accelerating technology verification and industrial application.